Skip to content
Products & Services · Total revenues

Other license programs — Total revenues

Alnylam Pharmaceuticals Other license programs — Total revenues increased by 439.7% to $39.7M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 198.0%, from $13.32M to $39.7M. Over 2 years (FY 2023 to FY 2025), Other license programs — Total revenues shows an upward trend with a 34.1% CAGR.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
Metric ID: alny_segment_other_license_programs_total_revenues

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$6.99M$6.99M$6.99M$6.99M$9.66M$3.11M$18.45M$1.92M$13.32M$19.59M$10M$7.36M$39.7M
QoQ Change+0.0%+0.0%+0.0%+38.2%-67.8%+493.4%-89.6%+594.3%+47.0%-48.9%-26.5%+439.7%
YoY Change+38.2%-55.5%+163.8%-72.6%+37.9%+529.9%-45.8%+283.3%+198.0%
Range$1.92M$39.7M
CAGR+78.4%
Avg YoY Growth+119.7%
Median YoY Growth+38.2%

Frequently Asked Questions

What is Alnylam Pharmaceuticals's other license programs — total revenues?
Alnylam Pharmaceuticals (ALNY) reported other license programs — total revenues of $39.7M in Q1 2026.
How has Alnylam Pharmaceuticals's other license programs — total revenues changed year-over-year?
Alnylam Pharmaceuticals's other license programs — total revenues increased by 198.0% year-over-year, from $13.32M to $39.7M.
What is the long-term trend for Alnylam Pharmaceuticals's other license programs — total revenues?
Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's other license programs — total revenues has grown at a 34.1% compound annual growth rate (CAGR), from $27.97M to $50.27M.